(Q33942996)

30 July 2017

1 reference

title

Challenges and opportunities for development of an AIDS vaccine (English)

1 reference

30 July 2017

0 references

1 reference

Nabel GJ

1

1 reference

PubMed ID

11309631

30 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

30 July 2017

1 reference

30 July 2017

410

1 reference

30 July 2017

6831

1 reference

30 July 2017

1002-1007

1 reference

https://scigraph.springernature.com/pub.10.1038/35073500

30 July 2017

0 references

cites work

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

1 reference

Extensive variation of human immunodeficiency virus type-1 in vivo

21 January 2018

1 reference

Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

21 January 2018

1 reference

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes

21 January 2018

1 reference

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes.

21 January 2018

1 reference

Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein

21 January 2018

1 reference

HIV-1 auxiliary proteins: making connections in a dying cell.

21 January 2018

1 reference

Neutralization of HIV-1 by antibody

21 January 2018

1 reference

A vaccine for HIV type 1: the antibody perspective

21 January 2018

1 reference

Antibody-dependent enhancement of infection and the pathogenesis of viral disease

21 January 2018

1 reference

Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk?

21 January 2018

1 reference

Sequence comparison of the phosphoprotein mRNAs of antigenic subgroups A and B of human respiratory syncytial virus identifies a highly divergent domain in the predicted protein

21 January 2018

1 reference

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

21 January 2018

1 reference

Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection

21 January 2018

1 reference

Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene

21 January 2018

1 reference

Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques

21 January 2018

1 reference

Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques

21 January 2018

1 reference

Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients

21 January 2018

1 reference

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort

21 January 2018

1 reference

HIV infection and pathogenesis: what about chemokines?

21 January 2018

1 reference

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

21 January 2018

1 reference

Progress in the development of an HIV-1 vaccine

21 January 2018

1 reference

Gene vaccination: plasmid DNA is more than just a blueprint

21 January 2018

1 reference

Genetic immunization is a simple method for eliciting an immune response

21 January 2018

1 reference

Heterologous protection against influenza by injection of DNA encoding a viral protein

21 January 2018

1 reference

Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity

21 January 2018

1 reference

DNA vaccines against malaria: immunogenicity and protection in a rodent model

21 January 2018

1 reference

Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein

21 January 2018

1 reference

Vaccination against tuberculosis by DNA injection

21 January 2018

1 reference

Immunization for Ebola virus infection

21 January 2018

1 reference

DNA immunization protects nonhuman primates against rabies virus

21 January 2018

1 reference

Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27.

21 January 2018

1 reference

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

21 January 2018

1 reference

Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates

21 January 2018

1 reference

Evaluation of recombinant alphaviruses as vectors in gene therapy

21 January 2018

1 reference

Sindbis virus vectors for expression in animal cells

21 January 2018

1 reference

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

21 January 2018

1 reference

Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy

21 January 2018

1 reference

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 January 2018

1 reference

Lentiviral vectors: turning a deadly foe into a therapeutic agent

21 January 2018

1 reference

AAV vectors: is clinical success on the horizon?

21 January 2018

1 reference

Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus

21 January 2018

1 reference

Adjuvants--a classification and review of their modes of action

21 January 2018

1 reference

Importance of the nef gene for maintenance of high virus loads and for development of AIDS

21 January 2018

1 reference

HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology.

21 January 2018

1 reference

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques

21 January 2018

1 reference

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

21 January 2018

1 reference

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

21 January 2018

1 reference

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

21 January 2018

1 reference

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

Atomic structure of the ectodomain from HIV-1 gp41

21 January 2018

1 reference

Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain

21 January 2018

1 reference

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket

21 January 2018

1 reference

Human studies in the development of human immunodeficiency virus vaccines

21 January 2018

1 reference

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

21 January 2018

1 reference

Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers

21 January 2018

1 reference

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

MHC-Restricted Cytotoxic T Cells: Studies on the Biological Role of Polymorphic Major Transplantation Antigens Determining T-Cell Restriction-Specificity, Function, and Responsiveness

21 January 2018

1 reference

7 January 2021

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

7 January 2021

HIV-1 antibody--debris or virion?

1 reference

7 January 2021

Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials

1 reference

7 January 2021

Declining CD4 T-cell counts in a person infected with nef-deleted HIV-1

1 reference

7 January 2021

Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection

1 reference

7 January 2021

1 reference

7 January 2021

Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines

1 reference

7 January 2021

DNA vaccination against persistent viral infection.

1 reference

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

7 January 2021

Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression

1 reference

7 January 2021

Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage

1 reference

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

7 January 2021

Fusion-competent vaccines: broad neutralization of primary isolates of HIV

1 reference

7 January 2021

Identifiers

DOI

10.1038/35073500

1 reference

PubMed ID

11309631

Dimensions Publication ID

30 July 2017

0 references

1 reference

PubMed ID

11309631